BioHarvest Sciences advances CDMO pharma deal to Stage 2, eyes scaled compound production

Proactive - Interviews for investors

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

17d ago 4:49

MP3•Episode home

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to announce a key advancement in the company’s contract development and manufacturing partnership with a Nasdaq-listed pharmaceutical company. The collaboration has now progressed from Stage 1 to Stage 2, marking a critical step forward in validating BioHarvest’s Botanical Synthesis platform for the development of pharmaceutical-grade active compounds. Stage 1 of the contract, which began in early 2024, focused on sourcing the appropriate plant species required to biosynthesize a compound used in an already approved pharmaceutical product. Sobel shared that the BioHarvest R&D team successfully completed this stage by isolating cells from the target plant and then replicating, enhancing, and multiplying those cells in laboratory conditions using its proprietary Botanical Synthesis technology. With Stage 1 successfully completed, Stage 2 is now underway and involves producing a sufficient quantity of biomass for pharmaceutical testing. This phase will also include optimizing the conditions for cultivating plant cells in liquid media to ensure consistent quality and yield. If successful, the project would move into scaled-up production—starting with small and medium volumes, followed by potential commercial-scale manufacturing of the compound. Sobel emphasized the significance of this milestone as further validation of BioHarvest’s Botanical Synthesis platform, which enables sustainable, controlled, and highly efficient production of complex plant-derived compounds without the need to cultivate full plants. “This advancement underscores our ability to address key challenges in pharmaceutical ingredient production and supports our broader goal of scaling up for commercial manufacturing,” Sobel said. As BioHarvest continues to deliver on its innovation roadmap, the CDMO contract signals a growing interest from the pharma industry in plant cell-based biosynthesis as a scalable alternative to traditional agricultural and chemical manufacturing methods. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #PlantBiotech #DrugDevelopment #CDMO #BioreactorTech #PhytoMedicine #ProactiveInvestors #BiotechUpdate #BotanicalSynthesis

607 episodes

#Trading #Business News #Business #News #Proactive Investors #Gold #Cannabis #Battery Metals #Chief Executive #Biotech #Natural Resources #Bitcoin #Cryptocurrency #Interviews #Investing #Investment Research #Mining #Retail Investment #Technology